The prognostic relevance of tumour-infiltrating plasma cells and immunoglobulin kappa C indicates an important role of the humoral immune response in non-small cell lung cancer

Cancer Letters

Volumn 333, Issue 2, 2013, Pages 222-228

  Lohr, Miriam ^a   Edlund, Karolina ^b   Botling, Johan ^b   Hammad, Seddik ^a,c   Hellwig, Birte ^a   Othman, Amnah ^a   Berglund, Anders ^d,e   Lambe, Mats ^d,e   Holmberg, Lars ^e,f   Ekman, Simon ^b   Bergqvist, Michael ^b   Pontén, Fredrik ^b   Cadenas, Cristina ^a   Marchan, Rosemarie ^a   Hengstler, Jan G ^a   Rahnenführer, Jörg ^a   Micke, Patrick ^b  

^a TU DORTMUND UNIVERSITY   (Germany)

^b UPPSALA UNIVERSITY   (Sweden)

^c South Valley University   (Egypt)

^d KAROLINSKA INSTITUTE   (Sweden)

^e Regional Cancer Center Uppsala Orebro   (Sweden)

^f KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Biomarker; Microarray; Prognosis; Tumour immunity

Indexed keywords

CD20 ANTIGEN; IMMUNOGLOBULIN KAPPA CHAIN; MESSENGER RNA; SYNDECAN 1;

ARTICLE; B LYMPHOCYTE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; GENE; GENE EXPRESSION; HISTOLOGY; HUMAN; HUMAN TISSUE; HUMORAL IMMUNITY; IGKC GENE; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL RATE; TUMOR IMMUNITY;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD20; B-LYMPHOCYTES; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNITY, HUMORAL; IMMUNOGLOBULIN KAPPA-CHAINS; LUNG NEOPLASMS; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED; PLASMA CELLS; PROGNOSIS; STROMAL CELLS; SYNDECAN-1; TISSUE ARRAY ANALYSIS;

EID: 84876724283     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.01.036     Document Type: Article

References (37)

1. Grivennikov S.I., Greten F.R., Karin M. Immunity, inflammation, and cancer. Cell 2010, 2010(140):883-899.
2. Suzuki K., Kachala S.S., Kadota K., Shen R., Mo Q., Beer D.G., Rusch V.W., Travis W.D., Adusumilli P.S. Prognostic immune markers in non-small cell lung cancer. Clin. Cancer Res. 2011, 17:5247-5256.
3. Sica A., Allavena P., Mantovani A. Cancer related inflammation: the macrophage connection. Cancer Lett. 2008, 267:204-215.
4. Petersen R.P., Campa M.J., Sperlazza J., Conlon D., Joshi M.B., Harpole D.H., Patz E.F. Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients. Cancer 2006, 107:2866-2872.
5. Zeni E., Mazzetti L., Miotto D., Lo Cascio N., Maestrelli P., Querzoli P., Pedriali M., De Rosa E., Fabbri L.M., Mapp C.E., Boschetto P. Macrophage expression of interleukin-10 is a prognostic factor in non-small cell lung cancer. Eur. Respir. J. 2007, 30:627-632.
6. Ho C.C., Liao W.Y., Wang C.Y., Lu Y.H., Huang H.Y., Chen H.Y., Chan W.K., Chen H.W., Yang P.C. TREM-1 expression in tumor-associated macrophages and clinical outcome in lung cancer. Am. J. Respir. Crit. Care Med. 2008, 177:763-770.
7. Ohri C.M., Shikotra A., Green R.H., Waller D.A., Bradding P. Macrophages within NSCLC tumour islets are predominantly of a cytotoxic M1 phenotype associated with extended survival. Eur. Respir. J. 2009, 33:118-126.
8. Hiraoka K., Miyamoto M., Cho Y., Suzuoki M., Oshikiri T., Nakakubo Y., Itoh T., Ohbuchi T., Kondo S., Katoh H. Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma. Brit. J. Cancer 2006, 94:275-280.
9. Dieu-Nosjean M.C., Antoine M., Danel C., Heudes D., Wislez M., Poulot V., Rabbe N., Laurans L., Tartour E., de Chaisemartin L., Lebecque S., Fridman W.H., Cadranel J. Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J. Clin. Oncol. 2008, 26:4410-4417.
10. Ruffini E., Asioli S., Filosso P.L., Lyberis P., Bruna M.C., Macrì L., Daniele L., Oliaro A. Clinical significance of tumor-infiltrating lymphocytes in lung neoplasms. Ann. Thorac. Surg. 2009, 87:365-371.
11. Wakabayashi O., Yamazaki K., Oizumi S., Hommura F., Kinoshita I., Ogura S., Dosaka-Akita H., Nishimura M. CD4+ T cells in cancer stroma, not CD8+ T cells in cancer cell nests, are associated with favorable prognosis in human non-small cell lung cancers. Cancer Sci. 2003, 94:1003-1009.
12. Lynch T.J., Bondarenko I., Luft A., Serwatowski P., Barlesi F., Chacko R., Sebastian M., Neal J., Lu H., Cuillerot J.M., Reck M. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J. Clin. Oncol. 2012, 30:2046-2054.
13. Robert C., Thomas L., Bondarenko I., O'Day S., M D J.W., Garbe C., Lebbe C., Baurain J.F., Testori A., Grob J.J., Davidson N., Richards J., Maio M., Hauschild A., Miller W.H., Gascon P., Lotem M., Harmankaya K., Ibrahim R., Francis S., Chen T.T., Humphrey R., Hoos A., Wolchok J.D. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. New Engl. J. Med. 2011, 364:2517-2526.
14. Whiteside T.L., Ferrone S. For breast cancer prognosis, immunoglobulin kappa chain surfaces to the top. Clin. Cancer Res. 2012, 18:2417-2419.
15. Schmidt M., Böhm D., von Törne C., Steiner E., Puhl A., Pilch H., Lehr H.A., Hengstler J.G., Kölbl H., Gehrmann M. The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Res. 2008, 68:5405-5413.
16. Schmidt M., Hellwig B., Hammad S., Othman A., Lohr M., Chen Z., Boehm D., Gebhard S., Petry I., Lebrecht A., Cadenas C., Marchan R., Stewart J.D., Solbach C., Holmberg L., Edlund K., Kultima H.G., Rody A., Berglund A., Lambe M., Isaksson A., Botling J., Karn T., Müller V., Gerhold-Ay A., Cotarelo C., Sebastian M., Kronenwett R., Bojar H., Lehr H.A., Sahin U., Koelbl H., Gehrmann M., Micke P., Rahnenführer J., Hengstler J.G. A comprehensive analysis of human gene expression profiles identifies stromal immunoglobulin κC as a compatible prognostic marker in human solid tumors. Clin. Cancer Res. 2012, 18:2695-2703.
17. Botling J., Edlund K., Lohr M., Hellwig B., Holmberg L., Lambe M., Berglund A., Ekman S., Bergqvist M., Pontén F., André König A.K., Fernandes O., Karlsson M., Helenius G., Karlsson C., Rahnenführer J., Hengstler J.G., Micke P. Biomarker discovery in non-small cell lung cancer: integrating gene expression profiling, meta-analysis and tissue microarray validation. Clin Cancer Res. 2013, 19:194-204.
18. Edlund K., Lindskog C., Saito A., Berglund A., Pontén F., Göransson-Kultima H., Isaksson A., Jirström K., Planck M., Johansson L., Lambe M., Holmberg L., Nyberg F., Ekman S., Bergqvist M., Landelius P., Lamberg K., Botling J., Ostman A. Micke P.CD99 is a novel prognostic stromal marker in non-small cell lung cancer. Int. J. Cancer 2012, 131:2264-2273.
19. Zhu C.Q., Ding K., Strumpf D., Weir B.A., Meyerson M., Pennell N., Thomas R.K., Naoki K., Ladd-Acosta C., Liu N., Pintilie M., Der S., Seymour L., Jurisica I., Shepherd F.A., Tsao M.S. Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer. J. Clin. Oncol. 2010, 28:4417-4424.
20. Raponi M., Zhang Y., Yu J., Chen G., Lee G., Taylor J.M., Macdonald J., Thomas D., Moskaluk C., Wang Y., Beer D.G. Gene expression signatures for predicting prognosis of squamous cell and adenocarcinomas of the lung. Cancer Res. 2006, 66:7466-7472.
21. Bild A.H., Yao G., Chang J.T., Wang Q., Potti A., Chasse D., Joshi M.B., Harpole D., Lancaster J.M., Berchuck A., Olson J.A., Marks J.R., Dressman H.K., West M., Nevins J.R. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 2006, 439:353-357.
22. Hou J., Aerts J., den Hamer B., van Ijcken W., den Bakker M., Riegman P., van der Leest C., van der Spek P., Foekens J.A., Hoogsteden H.C., Grosveld F., Philipsen S. Gene expression-based classification of non-small cell lung carcinomas and survival prediction. PLoS One 2010, 22:e10312.
23. Okayama H., Kohno T., Ishii Y., Shimada Y., Shiraishi K., Iwakawa R., Furuta K., Tsuta K., Shibata T., Yamamoto S., Watanabe S., Sakamoto H., Kumamoto K., Takenoshita S., Gotoh N., Mizuno H., Sarai A., Kawano S., Yamaguchi R., Miyano S., Yokota J. Identification of genes upregulated in ALK-positive and EGFR/KRAS/ALK-negative lung adenocarcinomas. Cancer Res. 2012, 72:100-111.
24. Director's Challenge Consortium for the Molecular Classification of Lung Adenocarcinoma, K. Shedden, J.M. Taylor, S.A. Enkemann, M.S. Tsao, T.J. Yeatman, W.L. Gerald, S. Eschrich, I. Jurisica, T.J. Giordano, D.E. Misek, A.C. Chang, C.Q. Zhu, D. Strumpf, S. Hanash, F.A. Shepherd, K. Ding, L. Seymour, K. Naoki, N. Pennell, B. Weir, R. Verhaak, C. Ladd-Acosta, T. Golub, M. Gruidl, A. Sharma, J. Szoke, M. Zakowski, V. Rusch, M. Kris, A. Viale, N. Motoi, W. Travis, B. Conley, V.E. Seshan, M. Meyerson, R. Kuick, K.K. Dobbin, T. Lively, J.W. Jacobson, D.G. Beer, Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study, Nat. Med. 14 (2008) 822-827.
25. Benjamini Y., Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. Journal of the Royal Statistical Society Series B 1995, 57:289-300.
26. Konopa K. Do we have markers to select patients for adjuvant therapies of non-small-cell lung cancer?. Ann. Oncol. 2010, 21(vii):199-202.
27. Pisters K.M., Le Chevalier T. Adjuvant chemotherapy in completely resected non-small-cell lung cancer. J. Clin. Oncol. 2005, 23:3270-3278.
28. Pardoll D.M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 2012, 12:252-264.
29. Mori M., Ohtani H., Naito Y., Sagawa M., Sato M., Fujimura S., Nagura H. Infiltration of CD8+ T cells in non-small cell lung cancer is associated with dedifferentiation of cancer cells, but not with prognosis. Tohoku J. Exp. Med. 2000, 191:113-118.
30. Kawai O., Ishii G., Kubota K., Murata Y., Naito Y., Mizuno T., Aokage K., Saijo N., Nishiwaki Y., Gemma A., Kudoh S., Ochiai A. Predominant infiltration of macrophages and CD8(+) T Cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer. Cancer 2008, 113:1387-1395.
31. Pelletier M.P., Edwardes M.D., Michel R.P., Halwani F., Morin J.E. Prognostic markers in resectable non-small cell lung cancer: a multivariate analysis. Can. J. Surg. 2001, 44:180-188.
32. Meek D.W., Marcar L. MAGE-A antigens as targets in tumour therapy. Cancer Lett. 2012, 324:126-132.
33. Jensen-Jarolim E., Singer J. Cancer vaccines inducing antibody production: more pros than cons. Expert Rev. Vaccines 2011, 10:1281-1289.
34. Sharma S., Srivastava M.K., Harris-White M., Lee J.M., Dubinett S. MUC1 peptide vaccine mediated antitumor activity in non-small cell lung cancer. Expert Opin. Biol. Ther. 2011, 11:987-990.
35. Karanikas V., Khalil S., Kerenidi T., Gourgoulianis K.I., Germenis A.E. Anti-survivin antibody responses in lung cancer. Cancer Lett. 2009, 282:159-166.
36. Türeci O., Mack U., Luxemburger U., Heinen H., Krummenauer F., Sester M., Sester U., Sybrecht G.W., Sahin U. Humoral immune responses of lung cancer patients against tumor antigen NY-ESO-1. Cancer Lett. 2006, 236:64-71.
37. De Pas T., Giovannini M., Rescigno M., Catania C., Toffalorio F., Spitaleri G., Delmonte A., Barberis M., Spaggiari L., Solli P., Veronesi G., De Braud F. Vaccines in non-small cell lung cancer: Rationale, combination strategies and update on clinical trials. Crit. Rev. Oncol. Hematol. 2012, 83:432-443.